Insider · CIK 0001181180
Peter S Kim
Files at TRDA (Entrada Therapeutics, Inc.). First filing Mar 21, 2024, latest Jun 18, 2025.
In brief
Peter S Kim files SEC Form 4 as director at TRDA (Entrada Therapeutics, Inc.). Since Mar 21, 2024, Peter S Kim has reported 3 open-market buys worth $890k and 0 open-market sells worth $0, the latest filed on Jun 18, 2025.
A track record needs three past buys with six months of prices behind them; Peter S Kim has 1, so none is measured yet.
The newest scored trade: bought $732k of TRDA on May 13, 2024, filed Jun 18, 2025, scored 46 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TRDA: Entrada Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | TRDAbuy Entrada Therapeutics, Inc. | $732k 50,000 shares | +74% | - | |
| 37Weak | TRDAbuy Entrada Therapeutics, Inc. | $123k 9,048 shares | +18% | +25% from low-24% from high | |
| 28Weak | TRDAbuy Entrada Therapeutics, Inc. | $35k 2,732 shares | +6% | +15% from low-29% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | TRDA Entrada Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 12, 2026 |
| May 13, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +25,000 | $14.68 | $367k | 92,412 | Jun 18, 2025 |
| May 14, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +25,000 | $14.59 | $365k | 117,412 | Jun 18, 2025 |
| Jun 11, 2025 | TRDA Entrada Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 12, 2025 |
| Mar 22, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +3,118 | $13.76 | $43k | 52,894 | Mar 26, 2024 |
| Mar 25, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +3,180 | $13.36 | $42k | 56,074 | Mar 26, 2024 |
| Mar 26, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +2,750 | $13.64 | $38k | 58,824 | Mar 26, 2024 |
| Mar 19, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +900 | $12.66 | $11k | 47,944 | Mar 21, 2024 |
| Mar 20, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +1,128 | $12.66 | $14k | 49,072 | Mar 21, 2024 |
| Mar 21, 2024 | TRDA Entrada Therapeutics, Inc. | POpen-market purchase Common Stock | +704 | $13.24 | $9,318 | 49,776 | Mar 21, 2024 |
Questions about Peter S Kim
Answered from the filings on this page, as of the latest one.
Is Peter S Kim buying or selling?
Not in the last 12 months. Peter S Kim's latest open-market trade on SEC Form 4 was bought $732k of TRDA on May 13, 2024.
How did Peter S Kim's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter S Kim has 1.
Where does Peter S Kim file Form 4?
Peter S Kim has filed Form 4 at TRDA (Entrada Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.